The stock of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a huge mover today! The stock increased 5.17% or $1.85 during the last trading session, reaching $37.65. About 384,976 shares traded. Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) has risen 12.40% since February 9, 2017 and is uptrending. It has underperformed by 4.30% the S&P500.The move comes after 7 months positive chart setup for the $1.53B company. It was reported on Feb, 9 by Barchart.com. We have $40.29 PT which if reached, will make NASDAQ:PCRX worth $106.89M more.
Among 31 analysts covering Abercrombie & Fitch Co. (NYSE:ANF), 7 have Buy rating, 9 Sell and 15 Hold. Therefore 23% are positive. Abercrombie & Fitch Co. had 114 analyst reports since August 7, 2015 according to SRatingsIntel. Robert W. Baird maintained it with “Neutral” rating and $15 target in Friday, September 22 report. The firm has “Hold” rating by FBR Capital given on Monday, May 29. The stock of Abercrombie & Fitch Co. (NYSE:ANF) has “Hold” rating given on Friday, November 17 by Standpoint Research. On Friday, August 25 the stock rating was upgraded by Citigroup to “Buy”. The stock has “Underperform” rating by Wolfe Research on Monday, November 20. The rating was maintained by Wunderlich with “Sell” on Saturday, August 15. The rating was downgraded by Standpoint Research to “Hold” on Thursday, September 24. The company was maintained on Monday, November 21 by Telsey Advisory Group. The firm earned “Hold” rating on Monday, November 13 by RBC Capital Markets. JP Morgan maintained the stock with “Neutral” rating in Monday, March 14 report. See Abercrombie & Fitch Co. (NYSE:ANF) latest ratings:
23/01/2018 Broker: RBC Capital Markets Rating: Hold New Target: $24.0 Maintain
22/01/2018 Broker: Jefferies Rating: Hold New Target: $20.0 Maintain
24/01/2018 Broker: Bank of America Old Rating: Underperform New Rating: Underperform Old Target: $9 New Target: $16 Maintain
19/01/2018 Broker: Argus Research Old Rating: Hold New Rating: Buy Upgrade
18/12/2017 Broker: Jefferies Rating: Hold New Target: $17.0 Maintain
21/11/2017 Broker: RBC Capital Markets Rating: Sector Perform Old Target: $14.00 New Target: $16.00 Maintain
20/11/2017 Broker: Bank of America Rating: Sell New Target: $9.0 Maintain
20/11/2017 Broker: Wolfe Research Rating: Underperform Old Target: $9.00 Maintain
20/11/2017 Broker: Telsey Advisory Group Rating: Market Perform Old Target: $12.00 New Target: $17.00 Maintain
20/11/2017 Broker: Citigroup Rating: Buy Old Target: $16 New Target: $18 Maintain
Analysts await Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) to report earnings on March, 7. They expect $-0.08 earnings per share, up 33.33% or $0.04 from last year’s $-0.12 per share. After $-0.11 actual earnings per share reported by Pacira Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -27.27% EPS growth.
Since August 15, 2017, it had 0 insider purchases, and 5 sales for $2.39 million activity. Another trade for 3,461 shares valued at $127,192 was sold by Williams Kristen Marie. STACK DAVID M also sold $1.16 million worth of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) on Wednesday, January 10. Shares for $14,858 were sold by Riker Lauren Bullaro. HASTINGS PAUL J had sold 1,044 shares worth $37,741 on Tuesday, August 22.
Among 22 analysts covering Pacira Pharmaceuticals (NASDAQ:PCRX), 11 have Buy rating, 1 Sell and 10 Hold. Therefore 50% are positive. Pacira Pharmaceuticals had 84 analyst reports since July 28, 2015 according to SRatingsIntel. The stock of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) has “Hold” rating given on Monday, January 29 by Canaccord Genuity. The company was maintained on Thursday, August 20 by Wedbush. H.C. Wainwright maintained Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) rating on Thursday, January 4. H.C. Wainwright has “Buy” rating and $55.0 target. The rating was maintained by Piper Jaffray with “Buy” on Wednesday, November 8. The firm has “Buy” rating by Wedbush given on Wednesday, December 20. The rating was maintained by Wedbush with “Buy” on Wednesday, May 24. The stock of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) has “Hold” rating given on Wednesday, November 8 by BMO Capital Markets. The firm has “Buy” rating given on Wednesday, October 11 by RBC Capital Markets. The company was initiated on Tuesday, January 3 by H.C. Wainwright. The rating was maintained by Piper Jaffray on Wednesday, August 2 with “Buy”.
Investors sentiment decreased to 1.39 in 2017 Q3. Its down 0.23, from 1.62 in 2017Q2. It dropped, as 35 investors sold Pacira Pharmaceuticals, Inc. shares while 37 reduced holdings. 29 funds opened positions while 71 raised stakes. 41.63 million shares or 5.80% more from 39.35 million shares in 2017Q2 were reported. Alyeska Investment Lp owns 638,943 shares or 0.19% of their US portfolio. Loring Wolcott & Coolidge Fiduciary Advisors Llp Ma holds 19 shares or 0% of its portfolio. Legacy Cap Partners accumulated 0.94% or 47,393 shares. Rice Hall James & Associates Ltd Liability invested 0.45% of its portfolio in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). 12,120 were accumulated by Avenir. Tiaa Cref Mgmt Limited Liability Company holds 188,919 shares. Piermont Capital Management reported 6,860 shares. Pointstate Cap Ltd Partnership has invested 0.36% in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Renaissance Technologies Limited Liability Corporation owns 374,500 shares. Jacobs Levy Equity Management holds 0.01% of its portfolio in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) for 7,280 shares. Waddell And Reed Fin holds 0.07% or 815,666 shares in its portfolio. Guggenheim has 0.01% invested in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) for 79,122 shares. Raymond James And Assoc owns 66,475 shares for 0% of their portfolio. Suffolk Capital Limited Liability Corporation holds 0.2% of its portfolio in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) for 40,291 shares. Samlyn Cap invested in 0.35% or 372,269 shares.
Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, makes, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. The company has market cap of $1.53 billion. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. It currently has negative earnings. The companyÂ’s lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia.
Investors sentiment increased to 1.24 in 2017 Q3. Its up 0.29, from 0.95 in 2017Q2. It improved, as 27 investors sold Abercrombie & Fitch Co. shares while 51 reduced holdings. 36 funds opened positions while 61 raised stakes. 66.34 million shares or 4.05% more from 63.76 million shares in 2017Q2 were reported. California State Teachers Retirement Sys holds 0% in Abercrombie & Fitch Co. (NYSE:ANF) or 124,323 shares. Alliancebernstein Ltd Partnership holds 88,940 shares. State Street owns 0% invested in Abercrombie & Fitch Co. (NYSE:ANF) for 2.06M shares. Piedmont Inv Advisors Limited Company accumulated 14,815 shares or 0% of the stock. Barclays Public Limited Co accumulated 233,616 shares. Robeco Institutional Asset Bv invested in 1.21M shares. Balyasny Asset Management has invested 0.02% in Abercrombie & Fitch Co. (NYSE:ANF). Pinebridge Ltd Partnership holds 104,296 shares. Gsa Capital Prns Limited Liability Partnership stated it has 33,223 shares or 0.03% of all its holdings. Southpoint Cap Advsr Ltd Partnership invested in 1.00 million shares. Gagnon Securities Ltd Limited Liability Company invested 0.13% in Abercrombie & Fitch Co. (NYSE:ANF). Geode Ltd Limited Liability Company holds 560,699 shares. Quinn Opportunity Prtnrs Ltd Llc accumulated 1.34 million shares. Toronto Dominion Bancshares reported 0% of its portfolio in Abercrombie & Fitch Co. (NYSE:ANF). Adirondack Tru holds 3 shares.
The stock increased 1.09% or $0.22 during the last trading session, reaching $20.35. About 684,557 shares traded. Abercrombie & Fitch Co. (NYSE:ANF) has declined 47.82% since February 9, 2017 and is downtrending. It has underperformed by 64.52% the S&P500.